Drug Trial Radar · NCT07589244
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
May 13, 2026
Primary completion
Dec 31, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).
Conditions
- HCC
Interventions
VRT106Drug
VRT106,Intravenous infusion
VRT106 in combination with camrelizumab and apatinibDrug
VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration
Investigator's Choice of Standard of CareDrug
At the investigator's discretion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting ToxicitiesTime frame: Dose-limiting toxicity (DLT) will be assessed within 56 days following the first administration of VRT106.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.